Therapeutic interventions against this early abnormality in patients with hematopoietic cancers by means of demethylating agents (decitabine and azacytidine) have not yielded conclusive results.103, 104, 105, 106 Although some studies suggest that TET2 mutations are associated with a better clinical response, such a treatment does not provide a survival benefit. This evidence concerns the gene TET2 and hematopoietic and lymphoid cell neoplasm.